Molecular mechanisms associated with breast cancer based on integrated gene expression profiling by bioinformatics analysis

References

• Aoki-Kinoshita KF, Kanehisa M. 2007. Gene annotation and pathway mapping in KEGG, Comparative genomics. New York (NY): Humana Press. p. 71–91.
   Google Scholar
• Bader GD, Hogue CW. 2003. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics 4:2.
   PubMed Web of Science ®Google Scholar
• Baek W-K, Kim D, Jung N, Yi YW, Kim JM, Cha SD, et al. 2003. Increased expression of cyclin G1 in leiomyoma compared with normal myometrium. American Journal of Obstetrics and Gynecology 188:634–639.
   PubMed Web of Science ®Google Scholar
• Best D, Roberts D. 1975. Algorithm AS 89: the upper tail probabilities of Spearman’s rho. Applied Statistics 24:377–379.
   Google Scholar
• Bolstad BM, Irizarry RA, Astrand M, Speed TP.2003. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19:185–193.
   PubMed Web of Science ®Google Scholar
• Brown HM, Dunning KR, Robker RL, Pritchard M, Russell DL. 2006. Requirement for ADAMTS-1 in extracellular matrix remodeling during ovarian folliculogenesis and lymphangiogenesis. Developmental Biology 300:699–709.
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Gucalp A, Traina TA. 2014. Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. Breast Cancer (Dove Med Press) 6:123.
   PubMedGoogle Scholar
• Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. 2006. Cell cycle control in breast cancer cells. Journal of Cellular Biochemistry 97:261–274.
   PubMed Web of Science ®Google Scholar
• Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. 2008. Cancer survival in five continents: a worldwide population-based study (CONCORD). The Lancet Oncology 9:730–756.
   PubMed Web of Science ®Google Scholar
• Cui W, Wang LH, Wen YY, Song M, Li BL, Chen XL, et al. 2010. Expression and regulation mechanisms of Sonic Hedgehog in breast cancer. Cancer Science 101:927–933.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. 2012. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352.
   PubMed Web of Science ®Google Scholar
• Fakhrejahani E, Toi M. 2014. Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Japanese Journal of Clinical Oncology 44:197–207.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 127:2893–2917.
   PubMed Web of Science ®Google Scholar
• Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al.2013. STRING v9. 1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Research 41:D808–D815.
   PubMed Web of Science ®Google Scholar
• Freitas VM, do Amaral JB, Silva TA, Santos ES, Mangone FR, de Jesus Pinheiro J, et al. 2013. Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion. Molecular Cancer 12:2.
   PubMed Web of Science ®Google Scholar
• Hussain HA, Harvey AJ. 2014. Evolution of breast cancer therapeutics: breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy. World Journal of Clinical Oncology 5:299–310.
   PubMedGoogle Scholar
• Iruela-Arispe ML, Carpizo D, Luque A. 2003. ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Annals of the New York Academy of Sciences 995:183–190.
   PubMed Web of Science ®Google Scholar
• Johnson WE, Li C, Rabinovic A. 2007. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8:118–127.
   PubMed Web of Science ®Google Scholar
• Kimura SH, Ikawa M, Ito A, Okabe M, Nojima H. 2001. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene 20:3290–3300.
   PubMed Web of Science ®Google Scholar
• Knowles LM, Smith JW. 2007. Genome-wide changes accompanying knockdown of fatty acid synthase in breast cancer. BMC Genomics 8:168.
   PubMed Web of Science ®Google Scholar
• Kohl M, Wiese S, Warscheid B. 2011. Cytoscape: software for visualization and analysis of biological networks, data mining in proteomics. New York (NY): Humana Press. p. 291–303.
   Google Scholar
• Kuo W-H, Chang Y-Y, Lai L-C, Tsai M-H, Hsiao CK, Chang K-J, et al. 2012. Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. PLoS One 7:e45831.
   PubMed Web of Science ®Google Scholar
• Lacroix M, Toillon R-A, Leclercq G. 2006. p53 and breast cancer, an update. Endocrine-Related Cancer 13:293–325.
   PubMed Web of Science ®Google Scholar
• Luque A, Carpizo DR, Iruela-Arispe ML. 2003. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. The Journal of Biological Chemistry 278:23656–23665.
   PubMed Web of Science ®Google Scholar
• Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, et al. 2012. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treatment Reviews 38:673–688.
   PubMed Web of Science ®Google Scholar
• Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, et al. 2001. Expression of METH-1 and METH-2 in pancreatic cancer. Clinical Cancer Research 7:3437–3443.
   PubMed Web of Science ®Google Scholar
• Merdad A, Karim S, Schulten H-J, Dallol A, Buhmeida A, Al-Thubaity F, et al.2014. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer: MMP-9 as a potential biomarker for cancer invasion and metastasis. Anticancer Research 34:1355–1366.
   PubMed Web of Science ®Google Scholar
• Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al.2005. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences of the United States of America 102:13550–13555.
   PubMed Web of Science ®Google Scholar
• Mohinta S, Wu H, Chaurasia P, Watabe K. 2007. Wnt pathway and breast cancer. Frontiers in Bioscience 12:4020–4033.
   PubMed Web of Science ®Google Scholar
• Nugent J, Alfa CE, Young T, Hyams JS. 1991. Conserved structural motifs in cyclins identified by sequence analysis. Journal of Cell Science 99:669–674.
   PubMed Web of Science ®Google Scholar
• Okamoto K, Prives C. 1999. A role of cyclin G in the process of apoptosis. Oncogene 18:4606–4615.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. 2000. Molecular portraits of human breast tumours. Nature 406:747–752.
   PubMed Web of Science ®Google Scholar
• Perrot-Applanat M, Di Benedetto M. 2012. Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell adhesion & migration 6:547–553.
   PubMed Web of Science ®Google Scholar
• Rocks N, Paulissen G, Quesada-Calvo F, Munaut C, Gonzalez M-LA, Gueders M, et al. 2008. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Research 68:9541–9550.
   PubMed Web of Science ®Google Scholar
• Seo H, Lee D, Lee H, Baek M, Bae S, Soh J, et al. 2005. Cyclin G1 overcomes radiation-induced G2 arrest and increases cell death through transcriptional activation of cyclin B1. Cell Death & Differentiation 13:1475–1484.
   PubMed Web of Science ®Google Scholar
• Sherr CJ. 2006. Divorcing ARF and p53: an unsettled case. Natural Reviews Cancer 6:663–673.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Nishida J-i, Ueoka Y, Kato K, Hachiya T, Kuriaki Y, et al. 1998. CyclinG contributes to G2/M arrest of cells in response to DNA damage. Biochemical and Biophysical Research Communications 242:529–533.
   PubMed Web of Science ®Google Scholar
• Smyth GK. 2004. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology 3:Article 3. doi: 10.2202/1544-6115.1027.
   PubMedGoogle Scholar
• Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 98:10869–10874.
   PubMed Web of Science ®Google Scholar
• Sørlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A, et al. 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America 100:8418–8423.
   PubMed Web of Science ®Google Scholar
• Speiser JJ, Ersahin C, Osipo C.2013. The functional role of Notch signaling in triple-negative breast cancer. Vitamins and Hormones 93:277–306.
   PubMed Web of Science ®Google Scholar
• Tamura K, Kanaoka Y, Jinno S, Nagata A, Ogiso Y, Shimizu K, et al. 1993. Cyclin G: a new mammalian cyclin with homology to fission yeast Cig1. Oncogene 8:2113–2118.
   PubMed Web of Science ®Google Scholar
• Terunuma A, Putluri N, Mishra P, Mathé EA, Dorsey TH, Yi M, et al. 2014. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. The Journal of Clinical Investigation 124:398–412.
   PubMed Web of Science ®Google Scholar
• Zhao L, Samuels T, Winckler S, Korgaonkar C, Tompkins V, Horne MC, et al. 2003. Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways1 1 DEQ from the American Cancer Society (RSG-98-254-04-MGO) and NIH (RO1 CA90367), and by a grant from the NIH to MCH (RO1 GM56900). Molecular Cancer Research 1:195–206.
   PubMed Web of Science ®Google Scholar